L3VLUP
ProSign in

IQV · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

IQVVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • IQV
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterIQVVRTX
Q3 202021 holders, $4.8bn31 holders, $21.9bn
Q4 202022 holders, $5.2bn30 holders, $18.4bn
Q1 202118 holders, $5.4bn31 holders, $15.4bn
Q2 202126 holders, $6.1bn30 holders, $12.7bn
Q3 202124 holders, $5.9bn35 holders, $10.1bn
Q4 202124 holders, $6.9bn28 holders, $12.4bn
Q1 202221 holders, $5.2bn23 holders, $16.1bn
Q2 202215 holders, $3.9bn25 holders, $18.1bn
Q3 202221 holders, $3.1bn22 holders, $18.4bn
Q4 202219 holders, $3.9bn28 holders, $18.4bn
Q1 202324 holders, $4.4bn26 holders, $21.4bn
Q2 202323 holders, $5.5bn27 holders, $24.7bn
Q3 202322 holders, $5.4bn33 holders, $24.3bn
Q4 202314 holders, $6.2bn32 holders, $28.6bn
Q1 202415 holders, $6.9bn31 holders, $29.8bn
Q2 202420 holders, $5.8bn29 holders, $33.4bn
Q3 202423 holders, $6.3bn27 holders, $33.5bn
Q4 202422 holders, $5.7bn26 holders, $28.5bn
Q1 202522 holders, $5.1bn21 holders, $35.4bn
Q2 202521 holders, $5.4bn21 holders, $32.3bn
Q3 202517 holders, $5.9bn22 holders, $25.9bn
Q4 202518 holders, $7.0bn26 holders, $31.8bn
Q1 202611 holders, $4.7bn25 holders, $31.8bn
Q2 202619 holders, $5.3bn26 holders, $34.6bn
IQV

Iqvia HLDGS Inc

Holders
21
Reported value
$5.4bn
Buyers
15
Sellers
7

Breadth +8 among 95 comparable managers.

Health care services and researchHealthcare: biopharma and medtech · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
21
Reported value
$32.3bn
Buyers
11
Sellers
11

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 33 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only IQV (12)

Appaloosa LP, Arrowstreet Capital LP, Brevan Howard Capital Management LP, D. E. Shaw & Co., Farallon Capital Management LLC, Glenview Capital Management LLC, Harris Associates LP, Markel Group Inc, Moore Capital Management LP, Schonfeld Strategic Advisors LLC, Two Sigma Advisers LP, Two Sigma Investments LP

Only VRTX (12)

ARK Investment Management LLC, Baillie Gifford & Co, Bridgewater Associates LP, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Janus Henderson Group Ltd, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →